SINGAPORE, Nov. 1, 2022 /PRNewswire/ — GenScript Biotech Corporation (“GenScript”, Stock Code: 1548.HK), a number one international biotechnology firm supported Chulalongkorn University, a research-intensive college in Thailand in creating human anti-SARS-CoV-2 antibodies with antibody manufacturing and characterization providers. The antibodies have been licensed to Hibiocy Co. Ltd., which additional developed them right into a nasal spray medical gadget named VAILL COVITRAP™. The Thai FDA has authorised VAILL COVITRAP™ as a Class 4 medical gadget, making Thailand the primary nation to approve the manufacturing of human monoclonal antibody-based COVID-19 nasal spray. The human anti-SARS-CoV-2 antibodies that are a vital a part of the VAILL COVITRAP™ nasal spray gadget have been developed by Dr. Trairak Pisitkun’s staff from Chulalongkorn University, Bangkok, Thailand. GenScript has supported the staff with antibody manufacturing and characterization through the early part of analysis and contributed to the event of VAILL COVITRAP™ by producing GMP-grade antibodies on their proprietary speedy manufacturing platform.
The staff from Chulalongkorn University, who developed the anti-SARS-CoV-2 antibodies, established a biotechnology firm named Biogenexis (BGX). After the success of the VAILL COVITRAP™ venture, GenScript and BGX at the moment are planning to set off a future long-term collaboration to develop bleeding-edge biomedical innovation, which incorporates therapeutic antibodies, superior skincare merchandise, vaccine-related supplies and IVD equipment growth and manufacturing within the close to future. BGX’s tasks shall be handled as high-priority tasks through the manufacturing slot scheduling and skilled personnel shall be assigned to deal with the tasks.
“The success of the VAILL COVITRAP™ project established solid trust with our partner at Chulalongkorn University, and we are delighted to embark on another long-term collaboration with the team in other biomedical innovation,” mentioned Mr. Johnson Wang, President of GenScript Asia Pacific. “GenScript and Biogenexis are eager to combine our complementary strengths to achieve more scientific breakthroughs.”
“We are now ready to launch our innovative approaches to tackle global challenges in health and disease, especially emerging viruses, cancer, and aging. With a strong partner like GenScript, we firmly believe our mission will be propelled forward with a great mind, technology, and persistence,” mentioned Dr. Trairak. “Biogenexis and GenScript are seamlessly aligned for the upcoming endeavors.”
GenScript Biotech Corporation
GenScript Biotech Corporation (HK.1548) is the world’s main know-how and service supplier of life science R&D and manufacture. Built upon its stable gene synthesis know-how, GenScript Biotech is split into 4 main platforms together with the life science service and product platform, the biologics contract growth and manufacturing group (CDMO) platform, the worldwide cell remedy platform and the economic synthesis organic product platform.
GenScript Biotech was based in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech’s business operations span over 100 nations and areas worldwide with authorized entities situated within the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and Ireland. GenScript Biotech gives premium, handy and dependable providers and merchandise for over 200,000 prospects.
As of June 30, 2022, GenScript Biotech had greater than 5,500 workers globally, over 38% of whom maintain grasp’s and/or Ph.D. levels. In addition, GenScript Biotech owns plenty of mental property rights, together with over 190 patents, over 820 pending patent functions and nice numbers of commerce secrets and techniques.
Driven by the company mission of “make people and nature healthier through biotechnology”, GenScript Biotech strives to turn out to be essentially the most reliable biotech firm on the earth. As of June 30, 2022, 74,700 peer-reviewed journal articles worldwide have cited GenScript Biotech’s providers and merchandise.
For extra data, please go to GenScript Biotech’s official web site
https://www.genscript.com
About Biogenexis
Biogenexis is a number one Thai biotechnology startup based mostly in Bangkok, Thailand. Biogenexis goals to develop “first-in-class” deep-tech innovation in superior analysis, prophylaxis, and remedy based mostly on state-of-the-art antibody applied sciences. We are visionary in designing revolutionary product-market match by a mixed deep understanding and integration of science and ingenuity. We craft an unique, revolutionary product through our customized design workflow to make our imaginative and prescient come to life.
https://biogenexis.com
